Suppr超能文献

肿瘤相关巨噬细胞×癌细胞杂交体在乳腺癌中可能获得癌症干细胞特性。

Tumor associated macrophage × cancer cell hybrids may acquire cancer stem cell properties in breast cancer.

机构信息

Department of Breast Surgery, Breast Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.

出版信息

PLoS One. 2012;7(7):e41942. doi: 10.1371/journal.pone.0041942. Epub 2012 Jul 25.

Abstract

Breast cancer is one of the most frequently diagnosed cancers among women, and metastasis makes it lethal. Tumor-associated macrophages (TAMs) that acquire an alternatively activated macrophage (M2) phenotype may promote metastasis. However, the underlying mechanisms are still elusive. Here, we examined how TAMs interact with breast cancer cells to promote metastasis. Immunohistochemistry was used to examine the expression of the M2-specific antigen CD163 in paraffin-embedded mammary carcinoma blocks to explore fusion events in breast cancer patients. U937 cells were used as a substitute for human monocytes, and these cells differentiated into M2 macrophages following phorbol 12-myristate 13-acetate (PMA) and M-CSF stimulation. M2 macrophages and the breast cancer cell lines MCF-7 and MDA-MB-231 fused in the presence of 50% polyethylene glycol. Hybrids were isolated by fluorescence-activated cell sorting, and the relevant cell biological properties were compared with their parental counterparts. Breast cancer stem cell (BCSC)-related markers were quantified by immunofluorescence staining, RT-PCR, quantitative RT-PCR and/or western blotting. The tumor-initiating and metastatic capacities of the hybrids and their parental counterparts were assessed in NOD/SCID mice. We found that the CD163 expression rate in breast cancer tissues varied significantly and correlated with estrogen receptor status (p<0.05). The fusion efficiency of either breast cancer cell line with M2 macrophages ranged from 1.81 to 6.47% in the presence of PEG, and no significant difference was observed between the breast cancer cell lines used (p>0.05). Characterization of the fusion hybrids revealed a more aggressive phenotype, including increased migration, invasion and tumorigenicity, but reduced proliferative ability, compared with the parental lines. The hybrids also gained a CD44(+)CD24(-/low) phenotype and over-expressed epithelial-mesenchymal transition-associated genes. These results indicate that TAMs may promote breast cancer metastasis through cell fusion, and the hybrids may gain a BCSC phenotype.

摘要

乳腺癌是女性最常见的癌症之一,转移使其致命。获得替代性激活的巨噬细胞(M2)表型的肿瘤相关巨噬细胞(TAMs)可能促进转移。然而,潜在的机制仍不清楚。在这里,我们研究了 TAMs 如何与乳腺癌细胞相互作用以促进转移。使用免疫组织化学检查石蜡包埋的乳腺癌块中 M2 特异性抗原 CD163 的表达,以探索乳腺癌患者中的融合事件。使用 U937 细胞作为人单核细胞的替代品,这些细胞在佛波醇 12-肉豆蔻酸 13-乙酸酯(PMA)和 M-CSF 刺激下分化为 M2 巨噬细胞。在 50%聚乙二醇存在下,M2 巨噬细胞和乳腺癌细胞系 MCF-7 和 MDA-MB-231 融合。通过荧光激活细胞分选分离杂种,并比较其与亲本细胞的相关细胞生物学特性。通过免疫荧光染色、RT-PCR、定量 RT-PCR 和/或 Western blot 定量乳腺癌干细胞(BCSC)相关标志物。在 NOD/SCID 小鼠中评估杂种及其亲本的肿瘤起始和转移能力。我们发现,乳腺癌组织中 CD163 的表达率差异显著,与雌激素受体状态相关(p<0.05)。在 PEG 存在下,任一乳腺癌细胞系与 M2 巨噬细胞的融合效率在 1.81%至 6.47%之间,使用的乳腺癌细胞系之间没有观察到显著差异(p>0.05)。融合杂种的特征表明,与亲本系相比,其具有更具侵袭性的表型,包括迁移、侵袭和致瘤性增加,但增殖能力降低。杂种还获得了 CD44(+)CD24(-/low)表型,并过表达上皮-间充质转化相关基因。这些结果表明,TAMs 可能通过细胞融合促进乳腺癌转移,并且杂种可能获得 BCSC 表型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3273/3405038/a73175fa8f4b/pone.0041942.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验